MONTREAL, December 23, 2022 (GLOBE NEWSWIRE) — Knight Therapeutics Inc., GUD (“Knight”), a Pan American (ex-USA) specialty pharmaceutical company, announced today that it has secured a $38.5 million five-year secured loan with International Finance Corporation (“IFC”) which is denominated in selected Latin American currencies. , a member of the World Bank Group, focuses on the private sector in emerging markets.

The IFC loan is denominated in Brazilian Real, Colombian Peso, Chilean Peso and Mexican Peso, with the Brazilian Real tranche accounting for approximately 50% of the loan and the remainder being split between the remaining currencies. The IFC Loan Maturity Date is October 15, 2027, with principal repayments beginning October 15, 2023. In addition, the loan has customary covenants and is secured by select assets of Knight, including cash collateral equal to 35% of the principal outstanding.

“We are pleased with the financial flexibility this partnership with IFC provides,” said Arvind Utchanah, Chief Financial Officer of Knight Therapeutics Inc. “The loan, combined with Knight’s existing cash position, further strengthens our balance sheet while providing a natural hedge against future ones Currency depreciation in the key markets in which we operate.”

About Knight Therapeutics Inc.

Headquartered in Montreal, Canada, Knight Therapeutics Inc. is a specialty pharmaceutical company focused on acquiring or in-licensing and commercializing pharmaceutical products for Canada and Latin America. Knight’s Latin American subsidiaries operate under United Medical, Biotoscana Farma and Laboratorio LKM. Knight Therapeutics Inc. shares trade on the TSX under the symbol GUD. For more information about Knight Therapeutics Inc., visit the company’s website at www.gud-knight.com or www.sedar.com.

Forward-Looking Statement

This document contains forward-looking statements about Knight Therapeutics Inc. and its subsidiaries. By their nature, these forward-looking statements are necessarily…